NEWS

MediLynx is proud to announce our partnership with the National Heart,
Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH)-funded Cardiothoracic
Surgical Trials Network (CTSN) to participate in a multicenter randomized clinical trial sub-
study: Anticoagulation for New-Onset Post-Operative Atrial Fibrillation after CABG (PACeS)
Digital Health Sub-study.

The overall objective of the Digital Health Sub-study is to quantify the
burden of post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft
surgery (CABG) among enrolled patients.

“The key to effective care management is to always look for better solutions through research. We at MediLynx are honored to be selected by the NHLBI/NIH-funded CTSN to collaborate with more than 25 academic institutions in this exciting research study. MediLynx and PocketECG were selected because of our modernized engineering and proven clinical efficacy in cardiac monitoring.” - Peter Pellerito, Chief Executive Officer, MediLynx.

CORPORATE OFFICE

6700 Pinecrest Drive
Suite 200
Plano, TX 75024

FOLLOW US ON

ABOUT US

MediLynx is setting the new standard for arrhythmia diagnostics through our robust services and technology, and extraordinary customer service.

All rights reserved

SAN FRANCISCO

251 Rhode Island Street
Suite 111
San Francisco, CA 94103

Be the first to get news and information from MediLynx

CONTACT NUMBERS

855-847-1009
24 hours a day, 7 days a week

PATIENT & PHYSICIAN SUPPORT

855-847-0780
Weekdays, 8 AM – 5 PM Central

GENERAL & BILLING INQUIRIES

COMPLIANCE HOTLINE

844-296-4069

STAY IN TOUCH

Let Us Be an Extension of Your Practice

24/7 Customer Service · Patient Billing Advocate · Billing Concierge

MediLynx Arrhythmia Diagnostics is a registered trademark of Medi-Lynx Cardiac Monitoring, LLC. 

© 2021 MediLynx Arrhythmia Diagnostics or its affiliates. All rights reserved. XXXX0000

medilynx.com

View our Press Release